Cannabis Use Disorder Tied to Higher Pain, Wound Risks After Surgery

Study Identifies Elevated Complication Rates in CUD Patients

Cannabis use disorder patients showed measurably higher rates of post-surgical pain and wound healing problems after body-contouring procedures. The research examined outcomes in patients who'd undergone abdominoplasty, panniculectomy, and related reconstructive surgeries, comparing complication rates between those with diagnosed CUD and control groups without the disorder.

The findings add to mounting evidence linking chronic heavy cannabis use to surgical risk factors. Body-contouring surgery carries baseline risks of wound dehiscence and infection. The procedures involve extensive tissue removal and repositioning, often after significant weight loss.

Pain Management Complications Drive Clinical Concern

Post-operative pain control emerged as a primary challenge in the CUD patient cohort. Patients with cannabis use disorder required different pain management protocols. They reported higher subjective pain scores in the immediate post-surgical period.

Chronic THC exposure downregulates CB1 and CB2 receptors, potentially altering pain perception and response to both opioid and non-opioid analgesics. Anesthesiologists have long observed that regular cannabis users often require higher doses of anesthesia and post-op pain medication. The mechanism likely involves cannabinoid receptor tolerance.

Wound Healing Deficits Linked to Immune Modulation

CUD patients demonstrated slower wound healing and higher rates of dehiscence and seroma formation. The study documented increased incidence of wound-related complications requiring secondary interventions, including drainage procedures and revision surgeries.

Cannabis compounds exert immunomodulatory effects that may impair the inflammatory phase of wound healing. THC and other cannabinoids suppress cytokine production and leukocyte migration—processes essential for debris clearance and tissue repair in the first 72 hours post-surgery.

Implications for Pre-Surgical Screening and Counseling

The findings suggest plastic surgeons should implement routine CUD screening before elective body-contouring procedures. Many surgical practices already require nicotine cessation six weeks pre-operatively due to similar wound-healing concerns. This research may prompt parallel protocols for cannabis use.

Surgeons may need to consider extended pre-operative abstinence periods for CUD patients or adjust surgical techniques to minimize tension on closure sites.

The American Society of Plastic Surgeons hasn't yet issued formal guidance on cannabis use and elective surgery. Individual practices are beginning to address the issue in informed consent discussions.

Limitations and Need for Prospective Data

The study relied on retrospective chart review and ICD-coded diagnoses of cannabis use disorder, which may undercount actual prevalence. Self-reported cannabis use is notoriously unreliable in medical settings, particularly in states where use remains illegal or stigmatized. The research didn't differentiate between combustion, vaporization, and edible consumption methods, which may have distinct pharmacokinetic effects on healing.

Prospective studies with standardized pre-operative cannabinoid testing and controlled post-op monitoring would strengthen the evidence base. These findings are observational. They can't establish causation, only association.

What Surgeons and Patients Should Watch

Plastic surgery societies will likely release updated guidance on cannabis screening within the next 12 months as more outcome data accumulates. Patients considering body-contouring surgery should disclose cannabis use frequency and recency to their surgical team. For full background on cannabis use disorder and associated health risks, see the CannIntel topic hub on Cannabis Use Disorder Health Risks.

CUD represents a modifiable surgical risk factor. It warrants the same pre-operative counseling and management as tobacco use.